Key Takeaways Alvotech revenues jumped over 200% in H1 2025, led by Simlandi and Selarsdi sales.Teva expects up to 12 biosimilar launches in the US and Europe between 2025 and 2027.ALVO shares are down 14% YTD, while TEVA has dropped 39%, both lagging the industry.Both Alvotech (ALVO) and Teva Pharmaceuticals (TEVA) operate in the biosimilar space, but their business models differ significantly.ALVO has built its revenue model around partnerships, relying on alliances with regional players to bring products ...